Search Result

Results for "

antihyperglycemic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (2) Amylases (1) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (14) Autophagy (5) Bacterial (2) Biochemical Assay Reagents (1) COX (2) Dipeptidyl Peptidase (11) Endogenous Metabolite (4) Ferroptosis (11) Fungal (1) GLP Receptor (1) Glucokinase (3) Glycosidase (12) GPR119 (1) GSK-3 (1) IKK (1) Isotope-Labeled Compounds (4) Lipoxygenase (1) Mitochondrial Metabolism (1) PI3K (3) PKC (1) Potassium Channel (1) PPAR (9) SGLT (3) TNF Receptor (3) TRP Channel (5)
By Research Areas:	Cancer (18) Cardiovascular Disease (6) Endocrinology (2) Infection (1) Inflammation/Immunology (13) Metabolic Disease (61) Neurological Disease (8)

By Targets:

AMPK (2)

Amylases (1)

Androgen Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (1)

Apoptosis (14)

Autophagy (5)

Bacterial (2)

Biochemical Assay Reagents (1)

COX (2)

Dipeptidyl Peptidase (11)

Endogenous Metabolite (4)

Ferroptosis (11)

Fungal (1)

GLP Receptor (1)

Glucokinase (3)

Glycosidase (12)

GPR119 (1)

GSK-3 (1)

IKK (1)

Isotope-Labeled Compounds (4)

Lipoxygenase (1)

Mitochondrial Metabolism (1)

PI3K (3)

PKC (1)

Potassium Channel (1)

PPAR (9)

SGLT (3)

TNF Receptor (3)

TRP Channel (5)

By Research Areas:

Cancer (18)

Cardiovascular Disease (6)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (13)

Metabolic Disease (61)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-121811

Pongamol Lanceolatin C	Glycosidase	Metabolic Disease Inflammation/Immunology
Pongamol (Lanceolatin C) is potent α-glucosidase inhibitor (IC₅₀=103.5 μM) and has free-radical (DPPH) scavenging,antihyperglycemic, and antihyperglycemic activities .

HY-B0089

Acarbose 3 Publications Verification BAY g 5421	Glycosidase	Metabolic Disease Cancer
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

HY-N0336A

(Z)-3-Butylidenephthalide (Z)-Butylidenephthalide	Glycosidase	Metabolic Disease
(Z)-3-Butylidenephthalide is an *antihyperglycemic* agent by inhibiting the activity of intestinal and yeast R-glucosidases (IC₅₀=2.35 mM; K_i=4.86 mM) .

HY-N0669

Stevioside 2 Publications Verification	Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Stevioside is an orally active sweetener that can be isolated from Stevia rebaudiana, with antihypertensive, antihyperglycemic, antioxidant, anti-inflammatory and anti-tumor activities .

HY-146128

Anti-hyperglycemic agent-1	Glycosidase	Metabolic Disease
Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC₅₀ of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .

HY-117460

Indanorex	Biochemical Assay Reagents	Others
Indanorex is a stimulant agent with appetite suppressant effects and antihyperglycemic effects .

HY-126807

AS1907417	GPR119	Metabolic Disease
AS1907417 is a novel GPR119 agonist with an oral activity. AS1907417 is a modified form of AS1269574. AS1907417 has antihyperglycemic and can be used in the research of type 2 diabetes .

HY-109060

Garvagliptin ZYDPLA1	Dipeptidyl Peptidase	Metabolic Disease
Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC₅₀ of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect .

HY-131488

8-Debenzoylpaeoniflorin	Others	Metabolic Disease
8-Debenzoylpaeoniflorin, a monoterpene glycoside, is a natural product that could be isolated from the dried root of Paeonia lactiflora Pall. 8-Debenzoylpaeoniflorin has antihyperglycemic activity .

HY-U00346A

TS-021	Dipeptidyl Peptidase	Metabolic Disease
TS-021 is a selective, orally active, reversible and long-acting DPP-IV inhibitor, and exhibits significant inhibition selectivity against DPP-8 (> 600 fold), DPP-9 (> 1200 fold) and other peptidases (> 15,000 fold). TS-021 inhibits DPP-IV activity in human plasma with an IC₅₀ value of 5.34 nM. TS-021 has long-term persistent plasma drug concentration and potent antihyperglycemic activity, and increases in the active form of GLP-1 .

HY-A0176

Glisoxepide	Potassium Channel	Cardiovascular Disease Metabolic Disease
Glisoxepide, a sulphonamide derivative, is an orally available nonselective K(ATP) channel blocker, with antihyperglycemic activity and cardiovascular regulation effect .

HY-14291

Vildagliptin 4 Publications Verification LAF237; NVP-LAF 237	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease Cancer
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-B0089R

Acarbose (Standard)	Glycosidase	Metabolic Disease Cancer
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-14291A

Vildagliptin dihydrate LAF237 dihydrate; NVP-LAF 237 dihydrate	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease Cancer
Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-N0669R

Stevioside (Standard)	Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Stevioside (Standard) is the analytical standard of Stevioside. This product is intended for research and analytical applications. Stevioside is an orally active sweetener that can be isolated from Stevia rebaudiana, with antihypertensive, antihyperglycemic, antioxidant, anti-inflammatory and anti-tumor activities .

HY-14291R

Vildagliptin (Standard)	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin (Standard) is the analytical standard of Vildagliptin. This product is intended for research and analytical applications. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-19394

CLX-0921	PPAR	Metabolic Disease
CLX-0921 is an orally active PPARγ agonist with an IC₅₀ of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .

HY-12608

TA-1887 JNJ-39933673	SGLT	Metabolic Disease
TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC₅₀: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes .

HY-14291B

(2R)-Vildagliptin (2R)-LAF237; (2R)-NVP-LAF 237	Others	Metabolic Disease
(2R)-Vildagliptin is the isomer of Vildagliptin (HY-14291), and can be used as an experimental control. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-121006

Biguanide	Mitochondrial Metabolism AMPK	Metabolic Disease Cancer
Biguanide is an orally active antihyperglycemic agent. Biguanide inhibits mitochondrial ATP production, activates the LKB1-AMPK signaling pathway, and damages the energy homeostasis. Biguanide exhibits potential in ameliorating the type 2 diabetes and the insulin-associated cancers .

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	Lipoxygenase	Metabolic Disease Cancer
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-157390

DPP-4-IN-9	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-9 (compound 6l) is a potent inhibitor of dipeptidyl peptidase DPP-4 (IC₅₀: 8.22 nM). DPP-4-IN-9 has antihyperglycemic activity .

HY-14860

1-Deoxynojirimycin 3 Publications Verification Duvoglustat	Glycosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-14860A

1-Deoxynojirimycin hydrochloride 3 Publications Verification Duvoglustat hydrochloride	Glycosidase PI3K Bacterial Antibiotic	Infection Metabolic Disease
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-123171

ASP8497	Dipeptidyl Peptidase	Metabolic Disease
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .

HY-14291S2

Vildagliptin-13C5,15N LAF237-¹³C₅,¹⁵N; NVP-LAF 237-¹³C₅,¹⁵N	Isotope-Labeled Compounds Dipeptidyl Peptidase Apoptosis Ferroptosis	Metabolic Disease
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14860R

1-Deoxynojirimycin (Standard)	Glycosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .

HY-N0547

Nomilin 1 Publications Verification	Others	Metabolic Disease
Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-101782

HSK0935	SGLT	Metabolic Disease
HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities .

HY-N0472

Geraniin 3 Publications Verification	TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC₅₀ of 43 μM.

HY-133127A

AR453588 hydrochloride	Glucokinase	Metabolic Disease
AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .

HY-133127

AR453588	Glucokinase	Metabolic Disease
AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity .

HY-N1185

Tagitinin A	Others	Metabolic Disease
Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .

HY-N10362

Ellipyrone B	Dipeptidyl Peptidase	Metabolic Disease
Ellipyrone B, an antihyperglycemic γ-pyrone enclosed macrocyclic polyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC₅₀=0.48 mM) .

HY-N8018

Leucosceptoside A	PKC Glycosidase Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Neurological Disease Metabolic Disease
Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC₅₀ of 19.0 μM) .

HY-N0547R

Nomilin (Standard)	Apoptosis IKK TNF Receptor	Metabolic Disease
Nomilin (Standard) is the analytical standard of Nomilin. This product is intended for research and analytical applications. Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-N0472R

Geraniin (Standard)	TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
Geraniin (Standard) is the analytical standard of Geraniin. This product is intended for research and analytical applications. Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC₅₀ of 43 μM.

HY-B0089A

Acarbose sulfate Bay-g 5421 sulfate	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC₅₀s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-19176

S-15261	Others	Metabolic Disease
S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .

HY-N13082

Deacetylescin Ia	Others	Metabolic Disease
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-N1390

Syringaldehyde	COX	Metabolic Disease Inflammation/Immunology
Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis . Syringaldehyde moderately inhibits COX-2 activity with an IC₅₀ of 3.5 μg/mL . Anti-hyperglycemic and anti-inflammatory activities .

HY-N3078

p-Hydroxyphenethyl trans-ferulate	Glycosidase	Endocrinology Cancer
p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemic (yeast α-glucosidase, IC₅₀=19.24 ± 1.73 µM), antioxidant, and anti-inflammatory activities . p-Hydroxyphenethyl trans-ferulate shows inhibiting anticancer and serotonergic activity .

HY-14291S1

Vildagliptin-d7 LAF237-d₇; NVP-LAF 237-d₇	Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin-d₇ is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

HY-126144

GSK-3β inhibitor 1 3 Publications Verification	GSK-3	Metabolic Disease Cancer
GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .

HY-14291S

Vildagliptin-d3 LAF237-d₃; NVP-LAF 237-d₃	Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin-d₃ is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].

HY-W068771

(E)-3-(4-Methoxyphenyl)acrylic acid	Endogenous Metabolite	Neurological Disease Metabolic Disease
(E)-3-(4-Methoxyphenyl)acrylic acid (compound 3) is isolated from Arachis hypogaea, Scrophularia buergeriana Miquel, Aquilegia vulgaris, Anigozanthos preissii and so on. (E)-3-(4-Methoxyphenyl)acrylic acid shows significant hepatoprotective activity, anti-amnesic, cognition-enhancing activity, antihyperglycemic, and neuroprotective activities .

Cat. No.	Product Name	Target	Research Area